Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydroxocobalamin acetate; moxidectin; selenium as sodium selenate; blackleg = clostridium chauvoei; enterotoxaemia = pulpy kidney = c perfringens; clostridium novyi type b; malignant oedema = clostridium septicum; tetanus = clostridium tetani; corynebacterium pseudotuberculosis (ovis) - toxoid; thiomersal - misc. vaccines or anti sera - hydroxocobalamin acetate vitamin-b12 active 1.0 mg/ml; moxidectin anthelmintic active 5.0 mg/ml; selenium as sodium selenate mineral-selenium active 1.0 mg/ml; blackleg = clostridium chauvoei vaccine-microbial active 0.0 p; enterotoxaemia = pulpy kidney = c perfringens vaccine-microbial active 0.0 p; clostridium novyi type b vaccine-microbial active 0.0 p; malignant oedema = clostridium septicum vaccine-microbial active 0.0 p; tetanus = clostridium tetani vaccine-toxoid active 0.0 p; corynebacterium pseudotuberculosis (ovis) - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.13 mg/ml - immuno+parasite+nutrition - sheep - not lambs | ewe | ovine | ram - barber's pole worm-haemonchus contortus | black disease | blackleg | brown stomach worm - ostertagia lyrata | caseous lymphadenitis (cheesy gland) | cooperia curticei | cooperia oncophora | enterotoxaemia (pulpy kidney) | intestinal hair worm - t. colubriformis | intestinal threadworm - s. papillosus | large bowel worm - o. venulosum | large lungworm - adult & l4 stages | large lungworm - dictyocaulus filaria | large mouth bowel worm - chabertia spp. | large mouthed bowel worm | malignant oedema | nasal bot | nematodirus abnormalis | nematodirus battus | nematodirus filicollis | nematodirus helvetianus | nodule worm - o. columbianum | ostertagia circumcincta | ostertagia trifurcata | selenium responsive condition | sheep itch mite | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | tetanus | thin necked intestinal worm | thin necked intestinal worm-n. spathiger | trichostrongylus rugatus | trichostrongylus spp. - adult/4th stage | vitamin b12 deficiency | w

Australija - engleski - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - potassium aspartate; magnesium aspartate; lysine-l hydrochloride; arginine-l hydrochloride; selenium as sodium selenate; vitamin b12 = cyanocobalamin; vitamin b3 = nicotinamide - parenteral liquid/solution/suspension - potassium aspartate amino acid-aspartate active 20.0 mg/ml; magnesium aspartate amino acid-aspartate active 20.0 mg/ml; lysine-l hydrochloride amino acid-lysine-l active 50.0 mg/ml; arginine-l hydrochloride amino acid-arginine-l active 100.0 mg/ml; selenium as sodium selenate mineral-selenium active 1.0 mg/ml; vitamin b12 = cyanocobalamin vitamin-b12 active 500.0 ug/ml; vitamin b3 = nicotinamide vitamin-b3 active 60.0 mg/ml - nutrition & metabolism - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - mineral and nutritional additive | acetonaemia | actinobacillosis | amino acid supplement | amino acids | bone fragility | bone growth | calcium supplement | cartilage strength | copper deficiency | egg shell | fatty acid deficiency | fatty liver | glucose | grass tetany | hepatotoxic drugs | hypocalcaemia | hypomagnesaemia | ileitis | iodine deficiencies | lactating | laxative | l-carnitine supplement | liver abscess | liver damage | lysine deficiencies | milk fever | mineral additive | myopathies | myositis syndrome | pangamic acid | phosphorous supplement | rickets | selenium deficiency | shell strength | soft bone disease | vitamin b12 | vitamin d supplement | vitamin e deficiencies | zinc deficiencies

Novi Zeland - engleski - Ministry for Primary Industries

elanco new zealand - sodium selenate; vitamin b12 - sodium selenate 4.8 g/litre; vitamin b12 1 g/litre - parenteral nutrient/electrolyte

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydroxocobalamin acetate; moxidectin; moxidectin concentrate; selenium as sodium selenate; blackleg = clostridium chauvoei; enterotoxaemia = pulpy kidney = c perfringens; clostridium novyi type b; malignant oedema = clostridium septicum; cla = corynebacterium pseudotuberculosis ovis; tetanus = clostridium tetani; thiomersal - parenteral liquid/solution/suspension - hydroxocobalamin acetate vitamin-b12 active 1.0 mg/ml; moxidectin anthelmintic active 2.5 mg/ml; moxidectin concentrate anthelmintic active 0.0 undefined; selenium as sodium selenate mineral-selenium active 0.5 mg/ml; blackleg = clostridium chauvoei vaccine-microbial active 0.0 undefined; enterotoxaemia = pulpy kidney = c perfringens vaccine-microbial active 0.0 undefined; clostridium novyi type b vaccine-microbial active 0.0 undefined; malignant oedema = clostridium septicum vaccine-microbial active 0.0 undefined; cla = corynebacterium pseudotuberculosis ovis vaccine-microbial active 0.0 undefined; tetanus = clostridium tetani vaccine-toxoid active 0.0 undefined; thiomersal mercury other 0.13 mg/ml - immuno+parasite+nutrition - lamb | ovine - barber's pole worm-haemonchus contortus | black scour worm - trichostrongylus spp. | brown stomach worm - ostertagia lyrata | cooperia curticei | cooperia oncophora | intestinal hair worm - t. colubriformis | intestinal threadworm - s. papillosus | large bowel worm - o. venulosum | large lungworm - dictyocaulus filaria | large mouthed bowel worm | nasal bot | nematodirus abnormalis | nematodirus battus | nematodirus filicollis | nematodirus helvetianus | nodule worm - o. columbianum | ostertagia circumcincta | ostertagia trifurcata | sheep itch mite | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | thin necked intestinal worm | thin necked intestinal worm-n. spathiger | trichostrongylus rugatus | trichostrongylus vitrinus | whipworm - trichuris ovis | black scour worm | psorobia ovis | sheep nasal bot fly | small brown stomach worm | small intestinal worm | teladorsagia | thin necked intestinal worm | thin necked intestinal worm-ad | trichostrongylus colu

Kanada - engleski - Health Canada

golden neo-life diamite international, limited - vitamin b12 (vitamin b12); nicotinamide; folic acid; d-pantothenic acid; choline bitartrate; selenium (sodium selenate); molybdenum (molybdenum trioxide); dl-methionine; vitamin b6 (pyridoxine hydrochloride); calcium (calcium phosphate (dibasic), calcium phosphate (tribasic), calcium carbonate); magnesium (magnesium oxide); phosphorus (calcium phosphate (dibasic), calcium phosphate (tribasic)); beta-carotene (provitamin a); vitamin a (retinol palmitate); ascorbic acid; vitamin d3; vitamin e (d-alpha tocopherol); vitamin b1 (thiamine mononitrate); vitamin b2 (vitamin b2); inositol; iron (ferrous fumarate); copper (cupric sulfate); zinc (zinc sulfate); potassium (potassium carbonate); iodine (potassium iodide); manganese (manganese sulfate); chromium (chromic chloride) - tablet - 30mcg; 100mg; .4mg; 50mg; 125mg; 50mcg; 100mcg; 1mg; 10mg; 230mg; 80mg; 125mg; 5000unit; 5000unit; 300mg; 400unit; 100unit; 7.5mg; 8.5mg; 125mg; 6mg; 3mg; 22.5mg; 50mg; 225mcg; 2mg; 50mcg - vitamin b12 (vitamin b12) 30mcg; nicotinamide 100mg; folic acid .4mg; d-pantothenic acid 50mg; choline bitartrate 125mg; selenium (sodium selenate) 50mcg; molybdenum (molybdenum trioxide) 100mcg; dl-methionine 1mg; vitamin b6 (pyridoxine hydrochloride) 10mg; calcium (calcium phosphate (dibasic), calcium phosphate (tribasic), calcium carbonate) 230mg; magnesium (magnesium oxide) 80mg; phosphorus (calcium phosphate (dibasic), calcium phosphate (tribasic)) 125mg; beta-carotene (provitamin a) 5000unit; vitamin a (retinol palmitate) 5000unit; ascorbic acid 300mg; vitamin d3 400unit; vitamin e (d-alpha tocopherol) 100unit; vitamin b1 (thiamine mononitrate) 7.5mg; vitamin b2 (vitamin b2) 8.5mg; inositol 125mg; iron (ferrous fumarate) 6mg; copper (cupric sulfate) 3mg; zinc (zinc sulfate) 22.5mg; potassium (potassium carbonate) 50mg; iodine (potassium iodide) 225mcg; manganese (manganese sulfate) 2mg; chromium (chromic chloride) 50mcg - vitamins & minerals

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

onpharma, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 84 mg in 1 ml - sodium bicarbonate inj., 8.4% usp neutralizing additive solution is indicated to hasten onset of analgesia and reduce injection pain, by adjusting commercial preparations of lidocaine w/ epinephrine anesthetic solution to a more physiologic ph. not for use as a systemic alkalizer. barash pg, cullen bf, stoelting rk, clinical anesthesia (4th ed. 2001 lippincott williams and wilken). bhatt h, powell kj, jean da, first aid for the anesthesiology boards, an insider's guide (2011, mcgraw-hill medical). cepeda ms, tzortzopoulou a, thackrey m, hudcova j, arora gandhi p, schumann r., adjusting the ph of lidocaine for reducing pain on injection. cochrane database of systematic reviews 2010, issue 12. art. no.: cd006581. chu lf, clinical anesthesiology board review(2005, mcgraw-hill medical). malamed sf,handbook of local anesthesiology(5th ed. 2004, elsevier mosby). miller rd, miller's anesthesia (6th ed. 2004). stoelting rk, miller rd,basics of anesthesia(5th ed. 2007, churchill livingstone el

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

mylan institutional llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. available data with sodium phenylacetate and sodium benzoate injection use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4%, and 15 to 20%, respectively. there are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for sodium phenylacetate and sodium benzoate injection and any potential adverse effects on the breastfed infant from sodium phenylacetate and sodium benzoate injection or from the underlying maternal condition. sodium phenylacetate and sodium benzoate injection has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [see dosage and administration (2) ]. clinical studies of sodium phenylacetate and sodium benzoate injection did not include any patients aged 65 and over to determine whether they respond differently from younger patients. urea cycle disorders are presently diseases of the pediatric and younger adult populations. no pharmacokinetic studies of sodium phenylacetate and sodium benzoate injection have been performed in geriatric patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population. pharmacokinetic parameters of sodium phenylacetate and sodium benzoate injection were compared in healthy males and females. bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. however, conclusions cannot be drawn due to the limited number of subjects in this study. limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. however, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. therefore, caution should be used in administering sodium phenylacetate and sodium benzoate injection to patients with hepatic insufficiency. the drug metabolites of sodium phenylacetate and sodium benzoate injection (phenylacetylglutamine and hippurate) and subsequently ammonia are primarily excreted by the kidney. therefore, use caution and closely monitor patients with impaired renal function who receive sodium phenylacetate and sodium benzoate injection.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

akorn - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 50 mg in 2 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition